Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bactrofor is a herbal phytoconcentrate developed by the Ukrainian company Ekomed in collaboration with the National Cancer Institute of Ukraine. It is classified as a dietary supplement and is intended for use in patients with various neoplasms (oncological diseases). The product is a complex mixture of plant extracts, including aloe, birch, knotgrass, St. John's wort, and nettle, designed to provide supportive care and potentially modulate the immune system during cancer treatment. As a phytoconcentrate, it does not have a single defined molecular mechanism of action but is marketed for its general health-restorative properties and its ability to support the body's natural defenses in the context of malignancy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bactrofor.